Skip to main content
NVONovo Nordisk A/SHold5.7·$42.18

Novo Nordisk A/S (NVO) Q3 2026 earnings — TrendMatrix coverage

BEAT+25.3% vs estimateEPS $5.79 vs $4.62 estCurrent verdict Hold 5.7/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q3 2026

Key numbers

Adjusted EPS
$5.79
Estimate
$4.62
Surprise
+25.3%
Score today
5.7/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q3 2026

How the report landed

Novo Nordisk A/S (NVO) beat the $4.62 estimate with adjusted EPS of $5.79 — a large 25.3% upside surprise.

Current read · as of 2026-11-05

Where TrendMatrix's rating stands now

TrendMatrix currently rates NVO Hold at 5.7/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +25.3% surprise compares with a +11.7% four-quarter average.

What supports the rating

  • V7 quality resilience bonus: +0.2 (Q=7.4 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Analyst target reached - limited upside remaining
  • Weak growth
  • Below 200-MA, MA slope -4.1%/30d (confirmed downtrend)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$42.18
Entry target
$41.30
Stop
$39.54

Forward estimates sit below the trailing run-rate (12.3× forward vs 10.7× trailing) — consensus expects earnings to decline from here.

Risk check: trading volume is running 2.4× its average — elevated turnover around the report window.

Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.

Healthcare context

NVO at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Drug Manufacturers - General
Market cap
$185.98B
P/E (fwd)
12.3
P/E (ttm)
10.7
52-week range
$35.12–$64.16
Off 52-week high
34.3%
RSI (14)
68
Volume vs avg
2.40×
Score today
5.7/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › NVO › Earnings › Q3 2026 earnings